Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 20/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 16/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3704517 | 0.79 | SCD (0.67) | — | |
| SCHEMBL3700480 | 0.78 | SCD (0.57) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| SCHEMBL9577755 | 0.77 | OPRD1 (0.59) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| SCHEMBL1236198 | 0.75 | SCD (0.54) | OPRD1KCNH2 | |
| SCHEMBL3703213 | 0.74 | SCD (0.46) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| SCHEMBL1237576 | 0.74 | OPRD1 (0.80) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| SCHEMBL3699798 | 0.73 | SCD (0.67) | — | |
| SCHEMBL3699800 | 0.73 | SCD (0.67) | — | |
| Lithium Ion SCHEMBL7399401 | 0.73 | OPRD1 (0.54) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| SCHEMBL3706923 | 0.72 | SCD (0.66) | OPRD1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383643-B2 | Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase | MERCK CANADA INC. (CA) | 2013-02-26 | — | — | US | disclosed |
| EP-2459568-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Limited (CA) | 2012-06-06 | — | — | EP | disclosed |
| US-20120122912-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC. (CA) | 2012-05-17 | — | — | US | disclosed |
| WO-2011011872-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122912-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | OPRD1 784/4885KCNH2 4330/4885OPRK1 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.